Monoclonal antibodies as potent therapeutics in dentistry.

  • Pratichi Tripathi Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Chandni Proothi Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Vathsala Patil Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • R. Vineetha Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.

References

1. Radfar L, Ahmadabadi RE, Masood F, Scofield RH. Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(5):594–601.
2. Kaur J, Badyal DK, Khosla PP. Monoclonal antibodies: Pharmacological relevance. Indian J Pharmacol. 2007;39(1):5–14.
3. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.
4. Yu KK, Crew AB, Messingham KAN, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–74.
5. Patil A, Prabhu V, Choudhari KS, Unnikrishnan VK, George SD, Ongole R, Pai KM, Shetty JK, Bhat S, Kartha VB, Chidangil S. Evaluation of high-perfor-mance liquid chromatography la-ser-induced fluorescence for serum protein profiling for early diagnosis of oral cancer. J Biomed Opt. 2010;15(6):067007.
6. Jan B. Vermorken. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. New Engl njournal Med Med. 2008;359(11):1116–27.
7. Chung CH1, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas. J Clin Oncol. 2006;24(25):4170-6.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.. Radiotherapy plus Cetuximab for Squamous- Cell Carcinoma of the Head and Neck. New Engl J Med. 2006;354(6):567–78.
9. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Anti-proliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer. 2002;101(6):567-75.
10. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646-54.
11. Khalifian S, Brazio PS, Mohan R, Shaffer C, Brandacher G, Barth RN, Rodriguez ED. Facial transplantation: the first 9 years. Lancet. 2014;384(9960):2153-63.
12. Booth V, Ashley FP, Lehner T. Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Infect Immun. 1996;64(2):422-7.
13. Gräber H, Becker C, Lampert F. Potential periodontal regeneration by application of monoclonal antibodies against integrin-subunits α 6 and β 1. Biomecánica. 2001;9(1):49-54.
14. Kim MA, Lee MJ, Jeong HK, Song HJ, Jeon HJ, Lee KY, Kim JG. A Monoclonal Antibody Specific to Glucosyltransferase B of Streptococcus mutans GS-5 and Its Glucosyltransferase Inhibitory Efficiency. Hybridoma. 2012;31(6):430-5.
15. Kishore M, Panat S, Aggarwal A, Agarwal N, Upadhyay N, Garg R. Sjogren′s syndrome: A review. SRM J Res Dent Sci. 2014;5(1):31.
16. Le Dantec C, Alonso R, Fali T, Montero E, Devauchelle V, Saraux A, Pers JO, Renaudineau Y. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res. 2013;56(2-3):341-7.
17. Steinfeld SD, Tant L, Burmester GR, Teoh NKW, Wegener WA, Goldenberg DM, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: An open-label phase I/II study. Arthritis Res Ther. 2006;8(4):1–11.
18. Ponticelli C, Moroni G. Monoclonal antibodies for systemic lupus erythematosus (SLE). Pharmaceuticals. 2010;3(1):300-22.
19. Gea-banacloche JC, Weinberg GA. OF Monoclonal Antibody Therapeutics and Risk for Infection. Pediatr Infect Dis J. 2007;26(11):1049–52.
20. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009 Jul;60(7):1884-94
21. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Discov. 2010;9:325-38.
Published
2019-11-18
How to Cite
TRIPATHI, Pratichi et al. Monoclonal antibodies as potent therapeutics in dentistry.. Journal of Oral Research, [S.l.], v. 8, n. 5, p. 344-347, nov. 2019. ISSN 0719-2479. Available at: <http://www.joralres.com/index.php/JOR/article/view/joralres.2019.053>. Date accessed: 10 aug. 2020. doi: https://doi.org/10.17126/joralres.2019.053.
Section
Perspectives